
TSE:NWH.UN
This summary was created by AI, based on 10 opinions in the last 12 months.
Northwest Health Prop Real Est Inv Trust (NWH.UN-T) has been undergoing significant transformation under new management, particularly a CEO with experience from Brookfield. The company is in a restructuring phase, focusing on its North American assets while divesting from international operations, which many analysts view as a necessary step due to previous over-leverage. Despite challenges, including increased debt servicing costs and a forced asset sale, the company appears to have stabilized operations. Analysts note a stable yield over 6%, with some optimism surrounding its long-term potential, although many express caution regarding immediate price appreciation. Overall, the company's diverse portfolio of medical assets presents opportunity, but future growth may hinge on its execution of strategic initiatives.
Large collection of healthcare real estate around the world. Inflation linked leases (good for income). Sticky tenants with doctors and healthcare. Problem is too much floating debt (higher interest rates). Recently replaced management team. Confident on business going forward. Expecting strength going forward. Book value is around $6-$7/share (trading around $4).
Messy. Cut dividend by 55%. Good lesson on chasing a too-high dividend yield. 97% occupancy, but not enough to keep them out of financial difficulties. $4B of debt, more than 1/3 at floating rates. Giant "For sale" sign on it. Insider selling in January. Facing tax-loss selling if things don't turn around.
The distribution cut was needed, but of course was fairly large (55%). The asset sales are a good start but challenges remain. The strategic review is only seven weeks old, but reading between the lines it sounds like there has not been huge interest yet. It is hard to endorse this right now. With higher rates and lower assets (from sales), growth will be hard to come by. We might be reluctant to sell it on the first trading day of this news, but we certainly think it can be 'targetted' for elimination from an investor's portfolio and used as a source of cash for other ideas. The stock will likely be in the penalty box for some time for multiple disappointments over the past year, with a business that is supposed to be more reliable and more predictable. We would not see solvency as an issue but it is just hard to like right now.
Unlock Premium - Try 5i Free
It has a 6.2% yield and he doesn't usually put higher yielding stocks into the equity platforms. This one came from the income platform. It fell so fast because it was over-leveraged but has now sold some of its assets. It is building a base and appears to be breaking out so he has bought two of the three legs. Buy 0 Hold 5 Sell 0
(Analysts’ price target is $5.85)